Research
Micronutrients & recovery
Specific hypoglycemic agents, SGLT-2 inhibitors and GLP-1 receptor agonists, reduce cardiovascular event risk in patients with diabetes, particularly those with a history of CVD, independent of glycemic control levels.
If you have diabetes and a history of heart disease, ask your doctor about SGLT-2 inhibitors or GLP-1 receptor agonists, as they may offer heart protection benefits beyond just lowering blood sugar.
GoodSupportsMEDIUM confidence
The sodium glucose co-transporter 2 (SGLT-2) inhibitors and the glucagon-like peptide 1 (GLP-1) receptor agonists have been associated with reduced risk of CVD events among persons with diabetes, particularly for persons with a history of CVD.
Why this rating
Based on association with reduced risk in trials, though detailed review is beyond scope.
Source
Management of Cardiovascular Risk in Perimenopausal Women with Diabetes
Catherine Kim · Diabetes & Metabolism Journal · 2021
narrative_reviewCited 18×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →